Skip to main content
SpringerLink
Log in

New index to assess the extent of bone disease in patients with prostate cancer using SPECT/CT

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Assessing the extent of bone metastases in patients with prostate cancer is very important to predict patient prognosis. Therefore, the bone scan index (BSI), which is easy to use, has been used; however, the accuracy is not that high. In this study, we proposed a new index for the extent of bone disease using single-photon emission computed tomography with computed tomography (SPECT/CT) images and assessed the accuracy of calculation.

Methods

In this study, a total of 46 bone scans from 12 patients with prostate cancer treated for bone metastases with Radium-223 were included. Whole-body planar images were obtained 150–180 min after an intravenous injection of 99mTc-methylene diphosphonate, and cervical-to-pelvic SPECT/CT was immediately obtained. The total bone volume (TBV) and regional metabolic bone volume (MBV) were defined as Hounsfield unit of > 120, standardized uptake value (SUV) of > 0.5, and SUV of > 5–8 in four levels, respectively. Bone metabolism volumetric index (BMVI) was calculated as the percentage of the total MBV divided by TBV. The variability of the TBV measurement was evaluated by the percentage coefficient of variance (%CV) of TBV within individual patients. We evaluated the correlation of TBV with age, height, weight, and body mass index and the correlation and agreement between BSI and BMVI.

Results

The mean and %CV of TBV were 4661.7 cm3 and 2.8%, respectively, and TBV was strongly correlated with body weight. BMVI was significantly higher than BSI and correlated with alkaline phosphatase. For patients with progressive bone metastases, BSI was clearly underestimated, whereas BMVI was elevated.

Conclusions

Although assessed in a small number of cases, the new index for assessing the extent of bone disease using SPECT/CT imaging was highly value than BSI and was significantly correlated with alkaline phosphatase. Therefore, this study suggests that BMVI could improve the low sensitivity of BSI in patients with low extent of disease grade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol. 2008;15:419–22.

    Article  CAS  Google Scholar 

  2. Erdi YE, Humm JL, Imbriaco M, Yeung H, Larson SM. Quantitative bone metastases analysis based on image segmentation. J Nucl Med. 1997;38:1401.

    CAS  PubMed  Google Scholar 

  3. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res. 1998;4:1765–72.

    CAS  PubMed  Google Scholar 

  4. Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30:519–24.

    Article  Google Scholar 

  5. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol. 2012;62:78–84.

    Article  Google Scholar 

  6. Horikoshi H, Kikuchi A, Onoguchi M, Sjostrand K, Edenbrandt L. Computer-aided diagnosis system for bone scintigrams from Japanese patients: importance of training database. Ann Nucl Med. 2012;26:622–6.

    Article  Google Scholar 

  7. Nakajima K, Nakajima Y, Horikoshi H, Ueno M, Wakabayashi H, Shiga T, et al. Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project. EJNMMI Res. 2013;3:83.

    Article  Google Scholar 

  8. Wakabayashi H, Nakajima K, Mizokami A, Namiki M, Inaki A, Taki J, et al. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Ann Nucl Med. 2013;27:802–7.

    Article  CAS  Google Scholar 

  9. Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, et al. Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:944–51.

    Article  Google Scholar 

  10. Kaboteh R, Damber JE, Gjertsson P, Hoglund P, Lomsky M, Ohlsson M, et al. Bone scan index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res. 2013;3:9.

    Article  Google Scholar 

  11. Sadik M, Suurkula M, Hoglund P, Jarund A, Edenbrandt L. Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study. J Nucl Med. 2009;50:368–75.

    Article  Google Scholar 

  12. Meirelles GS, Schoder H, Ravizzini GC, Gonen M, Fox JJ, Humm J, et al. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99 mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010;16:6093–9.

    Article  CAS  Google Scholar 

  13. Poulsen MH, Rasmussen J, Edenbrandt L, Høilund-Carlsen PF, Gerke O, Johansen A, et al. Bone scan index predicts outcome in patients with metastatic hormone-sensitive prostate cancer. BJU Int. 2016;117:748–53.

    Article  CAS  Google Scholar 

  14. Takahashi Y, Yoshimura M, Suzuki K, Hashimoto T, Hirose H, Uchida K, et al. Assessment of bone scans in advanced prostate carcinoma using fully automated and semi-automated bone scan index methods. Ann Nucl Med. 2012;26:586–93.

    Article  Google Scholar 

  15. Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238:264–71.

    Article  Google Scholar 

  16. Rager O, Nkoulou R, Exquis N, Garibotto V, Tabouret-Viaud C, Zaidi H, et al. Whole-body SPECT/CT versus planar bone scan with targeted SPECT/CT for metastatic workup. Biomed Res Int. 2017;2017:7039406.

    Article  Google Scholar 

  17. Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Turler A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41:59–67.

    Article  CAS  Google Scholar 

  18. Lofgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, et al. A prospective study comparing 99mTc-hydroxyethylene-diphosphonate planar bone scintigraphy and whole-body SPECT/CT with 18F-fluoride PET/CT and 18F-fluoride PET/MRI for diagnosing bone metastases. J Nucl Med. 2017;58:1778–85.

    Article  CAS  Google Scholar 

  19. Kaneta T, Ogawa M, Daisaki H, Nawata S, Yoshida K, Inoue T. SUV measurement of normal vertebrae using SPECT/CT with Tc-99 m methylene diphosphonate. Am J Nucl Med Mol Imaging. 2016;6:262–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Tsujimoto M, Teramoto A, Ota S, Toyama H, Fujita H. Automated segmentation and detection of increased uptake regions in bone scintigraphy using SPECT/CT images. Ann Nucl Med. 2018;32:182–90.

    Article  Google Scholar 

  21. Kuji I, Yamane T, Seto A, Yasumizu Y, Shirotake S, Oyama M. Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer. Eur J Hybrid Imaging. 2017;1:2.

    Article  Google Scholar 

  22. Umeda T, Koizumi M, Fukai S, Miyaji N, Motegi K, Nakazawa S, et al. Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients. Ann Nucl Med. 2018;32:105–13.

    Article  CAS  Google Scholar 

  23. Report of the task group on reference man. Ann ICRP. 1979;3(1–4):iii.

    Google Scholar 

  24. Tabotta F, Jreige M, Schaefer N, Becce F, Prior JO, Nicod LM. Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases. BMC Musculoskelet Disord. 2019;20:619.

    Article  CAS  Google Scholar 

  25. Shafi A, Thorsson O, Edenbrandt L. New routine for nuclear medicine technologists to determine when to add SPECT/CT to a whole-body bone scan. J Nucl Med Technol. 2014;42:28–32.

    Article  Google Scholar 

  26. Nakajima K, Edenbrandt L, Mizokami A. Bone scan index: a new biomarker of bone metastasis in patients with prostate cancer. Int J Urol. 2017;24:668–73.

    Article  Google Scholar 

  27. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948–948.

    Article  CAS  Google Scholar 

  28. Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi J, Kondo K, et al. Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC Cancer. 2016;16:128.

    Article  Google Scholar 

  29. Zacho HD, Manresa JAB, Aleksyniene R, Ejlersen JA, Fledelius J, Bertelsen H, et al. Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT. EJNMMI Res. 2017;7:1.

    Article  Google Scholar 

  30. Yamane T, Takahashi M, Matsusaka Y, Fukushima K, Seto A, Kuji I, et al. Satisfied quantitative value can be acquired by short-time bone SPECT/CT using a whole-body cadmium-zinc-telluride gamma camera. Sci Rep. 2021;11:24320.

    Article  CAS  Google Scholar 

  31. Ichikawa H, Miyaji N, Onoguchi M, Shibutani T, Nagaki A, Kato T, et al. Feasibility of ultra-high-speed acquisition in xSPECT bone algorithm: a phantom study with advanced bone SPECT-specific phantom. Ann Nucl Med. 2022;36:183–90.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Toyohashi Municipal Hospital, 50 Aza Hachiken Nishi, Aotake-Cho, Toyohashi, Aichi, 4418570, Japan

    Hajime Ichikawa & Yuki Taniguchi

  2. Department of Quantum Medical Technology, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, Ishikawa, 9200942, Japan

    Takayuki Shibutani & Masahisa Onoguchi

Authors
  1. Hajime Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takayuki Shibutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahisa Onoguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuki Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masahisa Onoguchi.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ichikawa, H., Shibutani, T., Onoguchi, M. et al. New index to assess the extent of bone disease in patients with prostate cancer using SPECT/CT. Ann Nucl Med 36, 941–950 (2022). https://doi.org/10.1007/s12149-022-01783-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-022-01783-z

Keywords

Search

Navigation